Veracyte Inc (VCYT)

May 8, 2025, 12:49 AM EDT - 3 days ago

Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 4 days ago

Veracyte Announces First Quarter 2025 Financial Results

Apr 25, 2025, 7:00 AM EDT - 16 days ago

Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer

Apr 22, 2025, 9:00 AM EDT - 19 days ago

Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting

Apr 21, 2025, 4:05 PM EDT - 20 days ago

Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release

Mar 25, 2025, 4:05 PM EDT - 6 weeks ago

New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer

Mar 19, 2025, 5:00 PM EDT - 7 weeks ago

Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

Feb 25, 2025, 10:32 AM EST - 2 months ago

Solid Growth, Soft Outlook: Why I'm Holding On Veracyte

Feb 25, 2025, 10:16 AM EST - 2 months ago

Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive

Feb 24, 2025, 10:53 PM EST - 2 months ago

Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 4:05 PM EST - 2 months ago

Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 19, 2025, 5:05 PM EST - 2 months ago

Veracyte to Participate in Upcoming Investor Conferences

Feb 14, 2025, 8:30 AM EST - 3 months ago

New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research

Feb 11, 2025, 8:30 AM EST - 3 months ago

Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests' Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium

Feb 5, 2025, 8:30 AM EST - 3 months ago

New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer

Feb 4, 2025, 4:30 PM EST - 3 months ago

Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025

Dec 5, 2024, 4:05 PM EST - 5 months ago

Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines

Nov 6, 2024, 10:49 PM EST - 6 months ago

Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:05 PM EST - 6 months ago

Veracyte Announces Third Quarter 2024 Financial Results

Oct 16, 2024, 6:43 PM EDT - 7 months ago

Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024

Sep 15, 2024, 8:45 AM EDT - 8 months ago

New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Sep 4, 2024, 4:05 PM EDT - 8 months ago

Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

Aug 26, 2024, 5:30 PM EDT - 9 months ago

Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 26, 2024, 9:00 AM EDT - 9 months ago

Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle

Aug 7, 2024, 2:08 PM EDT - 9 months ago

Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View

Aug 6, 2024, 10:17 PM EDT - 9 months ago

Veracyte, Inc. (VCYT) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 9 months ago

Veracyte Announces Second Quarter 2024 Financial Results

Jul 17, 2024, 5:00 PM EDT - 10 months ago

Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024

Jun 3, 2024, 4:05 PM EDT - 1 year ago

Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors

May 22, 2024, 4:05 PM EDT - 1 year ago

Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer

May 7, 2024, 4:05 PM EDT - 1 year ago

Veracyte Announces First Quarter 2024 Financial Results

May 6, 2024, 4:05 PM EDT - 1 year ago

14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

Apr 22, 2024, 5:00 PM EDT - 1 year ago

Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024

Apr 22, 2024, 8:30 AM EDT - 1 year ago

New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance

Apr 16, 2024, 8:30 AM EDT - 1 year ago

Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024

Feb 27, 2024, 5:55 PM EST - 1 year ago

Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines

Feb 22, 2024, 9:24 PM EST - 1 year ago

Veracyte, Inc. (VCYT) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 4:05 PM EST - 1 year ago

Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results

Feb 21, 2024, 5:00 PM EST - 1 year ago

Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference

Feb 8, 2024, 8:00 AM EST - 1 year ago

Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

Feb 6, 2024, 8:15 AM EST - 1 year ago

Veracyte Completes Acquisition of C2i Genomics

Jan 8, 2024, 8:00 AM EST - 1 year ago

Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform

Dec 12, 2023, 4:30 PM EST - 1 year ago

Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Dec 1, 2023, 4:05 PM EST - 1 year ago

Real-World Data Presented at SUO 2023 Show that Veracyte's Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress

Nov 29, 2023, 8:30 AM EST - 1 year ago

Clinical Validation Data Published in CHEST Demonstrate that Veracyte's Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules

Nov 22, 2023, 8:30 AM EST - 1 year ago

Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023

Nov 7, 2023, 8:57 PM EST - 1 year ago

Veracyte, Inc. (VCYT) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:05 PM EST - 1 year ago

Veracyte Announces Third Quarter 2023 Financial Results

Nov 7, 2023, 4:00 PM EST - 1 year ago

Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally

ILMN

Nov 2, 2023, 8:15 AM EDT - 1 year ago

Veracyte to Participate in the Stephens Annual Investment Conference